Filana Therapeutics, Inc. (FLNA) stock
Close on Nov 20, 2026Market cap $30.98MP/E –Yield –
Earnings
Filana Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Filana Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 11, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026before the open | – | – | -$0.22 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 29, 2026before the open | – | – | -$0.18 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | – | – | -$0.21 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 12, 2026before the open | – | – | -$0.26 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025before the open | – | – | -$0.22 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 14, 2025before the open | – | – | -$0.92 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025before the open | – | – | -$0.48 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 3, 2025before the open | – | – | -$0.57 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024before the open | – | – | -$0.58 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | – | – | $0.13 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 10, 2024after the close | – | – | -$0.43 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024before the open | – | – | -$0.50 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023before the open | – | – | -$0.61 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023before the open | – | – | -$0.63 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 1, 2023before the open | – | – | -$0.58 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023before the open | – | – | -$0.47 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 7, 2022before the open | – | – | -$0.51 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 3, 2022before the open | – | – | -$0.48 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022before the open | – | – | -$0.44 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 28, 2022after the close | – | – | -$0.35 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021before the open | – | – | -$0.24 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 3, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 21, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 23, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 9, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Filana Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| cash and cash equivalents | FY2026 | $38.00M – $42.00M | – | Raised | Nov 5, 2026 |
| net cash use in operations | FY2026 | $14.00M – $17.00M | – | New | Mar 12, 2026 |
| Net cash used in operations | FY2026 | $11.00M – $15.00M | $11.00M – $15.00M | Lowered | Nov 5, 2026 |
| unrestricted cash | FY2026 | $36.00M – $40.00M | – | Raised | Jul 29, 2026 |
Guidance history
Every forecast Filana Therapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | cash and cash equivalents | FY2026 | $38.00M – $42.00M | Raised |
| Nov 5, 2026 | Net cash used in operations | FY2026 | $11.00M – $15.00M | Lowered |
| Jul 29, 2026 | unrestricted cash | FY2026 | $36.00M – $40.00M | Raised |
| Jul 29, 2026 | Net cash used in operations | FY2026 | $11.00M – $15.00M | Lowered |
| Mar 12, 2026 | net cash use in operations | FY2026 | $14.00M – $17.00M | New |
| Nov 12, 2025 | incremental cash use | Q4 FY2025 | $10.00M – $14.00M | New |
| Nov 12, 2025 | cash | FY2025 | $92.00M – $96.00M | Raised |
| Aug 14, 2025 | Net cash used in operations | FY2025 | $47.00M – $51.00M | Raised |
| Aug 14, 2025 | cash | FY2025 | $61.00M – $65.00M | New |
| May 8, 2025 | Net cash used in operations | FY2025 | $16.00M – $20.00M | Reaffirmed |
| Mar 3, 2025 | Net cash use in operations | FY2025 | $16.00M – $20.00M | New |
| Nov 7, 2024 | Net cash used in operations | FY2024 | $40.00M – $50.00M | Raised |
| Nov 7, 2024 | cash and cash equivalents | Q4 FY2024 | $117.00M – $127.00M | New |
| May 10, 2024 | Net cash use in operations | FY2024 | $35.00M – $45.00M | Reaffirmed |
| Feb 28, 2024 | Cash use for operations | FY2024 | $35.00M – $45.00M | New |
| Nov 7, 2023 | Net cash use in operations | FY2023 | $40.00M – $50.00M | Reaffirmed |
| Aug 3, 2023 | Net cash use in operations | FY2023 | $40.00M – $50.00M | Raised |
| May 1, 2023 | net cash use in operations | FY2023 | $30.00M – $40.00M | Lowered |
| Feb 28, 2023 | Net cash use for operations | FY2023 | $45.00M – $50.00M | New |
| Nov 7, 2022 | Net cash use in operations | FY2022 | $80.00M – $90.00M | Reaffirmed |
| Aug 3, 2022 | Net cash use in operations | FY2022 | $80.00M – $90.00M | Raised |
| May 5, 2022 | Net cash use in operations | FY2022 | $35.00M – $40.00M | Raised |
| Feb 28, 2022 | Net cash use for operations | FY2022 | $25.00M – $35.00M | New |
| Nov 10, 2021 | Net cash use for operations | FY2021 | $25.00M – $30.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Filana Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Results
- Results
- Results
- Update
- Update
- Results
- Update
- Update
- Results
- Update
- Update
- Results
See a number that looks wrong?